Results 91 to 100 of about 224,992 (367)

The Association of Angiotension Converting Enzyme Gene Polimorphism with Prognosis of Henoch-Schönlein Purpura with Renal Involvement in the Children

open access: yesNamık Kemal Tıp Dergisi, 2020
Aim:Henoch-Schönlein purpura (HSP) is a vasculitis rarely progresses to renal failure. The mechanism of renal failure in HSP has been associated with increased angiotensin converting enzyme (ACE) activity and increased local angiotension-II concentration
Sevliya ÖCAL DEMİR, Müferet ERGÜVEN
doaj   +1 more source

Comparative analysis of recommendations for the management of patients with ANCA-associated vasculitis and kidney damage

open access: yesPočki, 2020
Antineutrophil cytoplasmic antibodies-associated vasculites (AAV) are a heterogeneous group of systemic necrotizing vasculites with a primary lesion of small vessels.
I.Yu. Golovach, Ye.D. Yehudina
doaj   +1 more source

Effect of long‐term voclosporin treatment on renal histology in patients with active lupus nephritis with repeat renal biopsies

open access: yesArthritis &Rheumatology, Accepted Article.
Objective This study characterized the impact of voclosporin on kidney histology in patients with lupus nephritis (LN) who had protocolized repeat kidney biopsies in the AURORA clinical trials. Methods Patients were randomized to voclosporin or placebo treatment for up to three years; all patients received mycophenolate mofetil and low‐dose ...
Brad H. Rovin   +9 more
wiley   +1 more source

Climate change and the kidney [PDF]

open access: yes, 2019
The worldwide increase in temperature has resulted in a marked increase in heat waves (heat extremes) that carries a markedly increased risk for morbidity and mortality.
Butler-Dawson, Jaime   +12 more
core   +1 more source

Lupus nephritis: challenges and progress.

open access: yesCurrent Opinion in Rheumatology, 2019
PURPOSE OF REVIEW The management of lupus nephritis remains unsatisfactory due to insufficiently effective treatment regimens and the dearth of reliable predictors of disease onset or progression to guide individualized therapeutic decisions. This review
A. Davidson, C. Aranow, M. Mackay
semanticscholar   +1 more source

Differences in dynamics of specific anti‐nuclear antibodies and their susceptibility to B cell targeting treatment in Systemic Lupus Erythematosus

open access: yesArthritis &Rheumatology, Accepted Article.
Objective The presence of anti‐nuclear antibodies (ANAs) is characteristic for systemic lupus erythematosus (SLE). Antibody dynamics over time are thought to reflect the cellular source of ANAs and their therapeutic targetability. Anti‐dsDNA is the most prevalent and well‐studied of all ANAs, and fluctuations in anti‐dsDNA serum levels are associated ...
Hugo J. van Dooren   +16 more
wiley   +1 more source

Wars, disasters and kidneys [PDF]

open access: yes, 2014
This paper summarizes the impact that wars had on the history of nephrology, both worldwide and in the Ghent Medical Faculty notably on the definition, research and clinical aspects of acute kidney injury.
Lameire, Norbert
core   +2 more sources

Freqüência de síndrome metabólica em pacientes com nefrite lúpica Frequency of metabolic syndrome in patients with lupus nephritis

open access: yesRevista Brasileira de Reumatologia, 2008
INTRODUÇÃO: Os pacientes com lúpus eritematoso sistêmico (LES) apresentam morbimortalidade importante por doenças cardiovasculares (DCV). A síndrome metabólica (SM) é um transtorno complexo representado por um conjunto de fatores de risco para DCV ...
Bernardo Matos da Cunha   +6 more
doaj   +1 more source

The Network of Inflammatory Mechanisms in Lupus Nephritis

open access: yesFrontiers in Medicine, 2020
Several signaling pathways are involved in the progression of kidney disease in humans and in animal models, and kidney disease is usually due to the sustained activation of these pathways.
Yuji Nozaki
doaj   +1 more source

Tough Decision Making in Pembrolizumab-Associated Acute Interstitial Nephritis: A Case Report

open access: yesRevista Portuguesa de Nefrologia e Hipertensão, 2023
Pembrolizumab is an immune checkpoint inhibitor used as a cancer therapy. The incidence of immune related adverse events in patients receiving immune checkpoint inhibitors can be as high as 59%–85%.
João Grilo   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy